IL119989A0 - Pharmaceutical compositions for oral treatment of multiple sclerosis - Google Patents
Pharmaceutical compositions for oral treatment of multiple sclerosisInfo
- Publication number
- IL119989A0 IL119989A0 IL11998997A IL11998997A IL119989A0 IL 119989 A0 IL119989 A0 IL 119989A0 IL 11998997 A IL11998997 A IL 11998997A IL 11998997 A IL11998997 A IL 11998997A IL 119989 A0 IL119989 A0 IL 119989A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- multiple sclerosis
- oral treatment
- treatment
- oral
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000037406 food intake Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Peptides Or Proteins (AREA)
- General Preparation And Processing Of Foods (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11998997A IL119989A0 (en) | 1997-01-10 | 1997-01-10 | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| EA199900621A EA003128B1 (ru) | 1997-01-10 | 1998-01-12 | Способ лечения рассеянного склероза и фармацевтический состав, содержащий сополимер-1 |
| KR1019997006278A KR20000070058A (ko) | 1997-01-10 | 1998-01-12 | 공중합체-1의 섭취 또는 흡입을 통한 다발성 경화증의 치료 |
| CNB988031221A CN100528222C (zh) | 1997-01-10 | 1998-01-12 | 共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途 |
| HK00104810.0A HK1025737B (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion of copolymer-1 |
| PL334566A PL193300B1 (pl) | 1997-01-10 | 1998-01-12 | Zastosowanie octanu glatirameru oraz kompozycja farmaceutyczna |
| EP98901745A EP0975351B1 (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion of copolymer-1 |
| AT98901745T ATE356608T1 (de) | 1997-01-10 | 1998-01-12 | Behandlung der multiplen sklerose durch einnahme von copolymer-1 |
| US09/341,369 US6214791B1 (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| CA2277365A CA2277365C (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| NZ336690A NZ336690A (en) | 1997-01-10 | 1998-01-12 | Copolymer-1 [glatiramer acetate (trade name Copaxone)] consists of L-glutamic acid, L-alanine, L-tryrosine and L-lysine for treating multiple sclerosis |
| CZ0243799A CZ297983B6 (cs) | 1997-01-10 | 1998-01-12 | Entericky potazená farmaceutická kompozice pro perorální podávání pro lécení roztrousené sklerózy |
| HU0001917A HU226612B1 (en) | 1997-01-10 | 1998-01-12 | Use of glatiramer acetate for production of pharmaceutical composition to the treatment of multiple sclerosis |
| ZA9800214A ZA98214B (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1. |
| PCT/US1998/000375 WO1998030227A1 (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| DE69837324T DE69837324T2 (de) | 1997-01-10 | 1998-01-12 | Behandlung der multiplen sklerose durch einnahme von copolymer-1 |
| JP53110898A JP4216342B2 (ja) | 1997-01-10 | 1998-01-12 | コポリマー１の摂取又は吸入を通じての多発性硬化症の治療 |
| BRPI9807076A BRPI9807076B8 (pt) | 1997-01-10 | 1998-01-12 | "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica" |
| SK931-99A SK284029B6 (sk) | 1997-01-10 | 1998-01-12 | Farmaceutická kompozícia na liečenie roztrúsenej sklerózy |
| IL13082098A IL130820A0 (en) | 1997-01-10 | 1998-01-12 | Pharmaceutical composition for oral treatment of multiple sclerosis |
| AU58195/98A AU737287B2 (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL130820A IL130820A (en) | 1997-01-10 | 1999-07-06 | Pharmaceutical preparations for the oral treatment of multiple sclerosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11998997A IL119989A0 (en) | 1997-01-10 | 1997-01-10 | Pharmaceutical compositions for oral treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL119989A0 true IL119989A0 (en) | 1997-04-15 |
Family
ID=11069682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11998997A IL119989A0 (en) | 1997-01-10 | 1997-01-10 | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| IL130820A IL130820A (en) | 1997-01-10 | 1999-07-06 | Pharmaceutical preparations for the oral treatment of multiple sclerosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL130820A IL130820A (en) | 1997-01-10 | 1999-07-06 | Pharmaceutical preparations for the oral treatment of multiple sclerosis |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0975351B1 (https=) |
| JP (1) | JP4216342B2 (https=) |
| KR (1) | KR20000070058A (https=) |
| CN (1) | CN100528222C (https=) |
| AT (1) | ATE356608T1 (https=) |
| AU (1) | AU737287B2 (https=) |
| BR (1) | BRPI9807076B8 (https=) |
| CA (1) | CA2277365C (https=) |
| CZ (1) | CZ297983B6 (https=) |
| DE (1) | DE69837324T2 (https=) |
| EA (1) | EA003128B1 (https=) |
| HU (1) | HU226612B1 (https=) |
| IL (2) | IL119989A0 (https=) |
| NZ (1) | NZ336690A (https=) |
| PL (1) | PL193300B1 (https=) |
| SK (1) | SK284029B6 (https=) |
| WO (1) | WO1998030227A1 (https=) |
| ZA (1) | ZA98214B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| WO2000005249A2 (en) * | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6872739B1 (en) * | 1999-06-04 | 2005-03-29 | Vereniging Voor Christelijk Wetenshappelikjk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
| JP2003522121A (ja) * | 1999-06-04 | 2003-07-22 | フェレニヒング フォール クリステレイク ウェテンスハッペリキク オンデルウェイス | 多発性硬化症の処置のためのリルゾールの使用 |
| IL150895A0 (en) * | 2000-02-18 | 2003-02-12 | Teva Pharma | Oral, nasal and pulmonary formulations of copolymer-1 |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| HUP0302333A3 (en) * | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| DK1485127T3 (da) | 2002-02-25 | 2011-10-03 | Elan Pharm Inc | Anvendelse af midler til behandling af inflammation |
| CA2514117A1 (en) * | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CN105884866B (zh) * | 2015-01-26 | 2021-04-20 | 漳州未名博欣生物医药有限公司 | 格拉替雷的化学合成方法 |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN112649538B (zh) * | 2015-04-28 | 2024-03-29 | 深圳翰宇药业股份有限公司 | 多肽混合物高效液相色谱分析方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US5719296A (en) * | 1995-10-30 | 1998-02-17 | Merck & Co., Inc. | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins |
-
1997
- 1997-01-10 IL IL11998997A patent/IL119989A0/xx unknown
-
1998
- 1998-01-12 SK SK931-99A patent/SK284029B6/sk not_active IP Right Cessation
- 1998-01-12 EP EP98901745A patent/EP0975351B1/en not_active Expired - Lifetime
- 1998-01-12 EA EA199900621A patent/EA003128B1/ru not_active IP Right Cessation
- 1998-01-12 PL PL334566A patent/PL193300B1/pl unknown
- 1998-01-12 WO PCT/US1998/000375 patent/WO1998030227A1/en not_active Ceased
- 1998-01-12 CZ CZ0243799A patent/CZ297983B6/cs not_active IP Right Cessation
- 1998-01-12 ZA ZA9800214A patent/ZA98214B/xx unknown
- 1998-01-12 BR BRPI9807076A patent/BRPI9807076B8/pt not_active IP Right Cessation
- 1998-01-12 JP JP53110898A patent/JP4216342B2/ja not_active Expired - Lifetime
- 1998-01-12 AT AT98901745T patent/ATE356608T1/de not_active IP Right Cessation
- 1998-01-12 CA CA2277365A patent/CA2277365C/en not_active Expired - Lifetime
- 1998-01-12 KR KR1019997006278A patent/KR20000070058A/ko not_active Ceased
- 1998-01-12 DE DE69837324T patent/DE69837324T2/de not_active Expired - Lifetime
- 1998-01-12 AU AU58195/98A patent/AU737287B2/en not_active Expired
- 1998-01-12 HU HU0001917A patent/HU226612B1/hu unknown
- 1998-01-12 NZ NZ336690A patent/NZ336690A/en not_active IP Right Cessation
- 1998-01-12 CN CNB988031221A patent/CN100528222C/zh not_active Expired - Lifetime
-
1999
- 1999-07-06 IL IL130820A patent/IL130820A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ336690A (en) | 2001-05-25 |
| SK93199A3 (en) | 2000-11-07 |
| WO1998030227A1 (en) | 1998-07-16 |
| AU5819598A (en) | 1998-08-03 |
| PL193300B1 (pl) | 2007-01-31 |
| EP0975351A1 (en) | 2000-02-02 |
| EP0975351B1 (en) | 2007-03-14 |
| EA199900621A1 (ru) | 2000-02-28 |
| HUP0001917A3 (en) | 2001-12-28 |
| BR9807076A (pt) | 2000-05-02 |
| HU226612B1 (en) | 2009-04-28 |
| DE69837324D1 (de) | 2007-04-26 |
| KR20000070058A (ko) | 2000-11-25 |
| ATE356608T1 (de) | 2007-04-15 |
| HUP0001917A2 (hu) | 2000-10-28 |
| JP2001511121A (ja) | 2001-08-07 |
| SK284029B6 (sk) | 2004-08-03 |
| PL334566A1 (en) | 2000-03-13 |
| BR9807076B1 (pt) | 2013-10-29 |
| EP0975351A4 (en) | 2002-05-15 |
| CZ243799A3 (cs) | 2000-06-14 |
| AU737287B2 (en) | 2001-08-16 |
| BRPI9807076B8 (pt) | 2021-05-25 |
| ZA98214B (en) | 1999-08-11 |
| CN1249690A (zh) | 2000-04-05 |
| IL130820A (en) | 2007-03-08 |
| HK1025737A1 (en) | 2000-11-24 |
| JP4216342B2 (ja) | 2009-01-28 |
| EA003128B1 (ru) | 2003-02-27 |
| CN100528222C (zh) | 2009-08-19 |
| CZ297983B6 (cs) | 2007-05-16 |
| CA2277365C (en) | 2011-04-12 |
| CA2277365A1 (en) | 1998-07-16 |
| DE69837324T2 (de) | 2007-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL119989A0 (en) | Pharmaceutical compositions for oral treatment of multiple sclerosis | |
| IL113812A (en) | Copolymer-1 pharmaceutical compositions containing it and its use | |
| GB0129260D0 (en) | Pharmaceutical compositions and their uses | |
| UA39158C2 (uk) | Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі | |
| BG103793A (en) | COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS | |
| IL108007A (en) | USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | |
| ZA943744B (en) | Therapeutic substituted guanidines | |
| HU9303357D0 (en) | Pharmaceutical composition containing well-defined lipide-systhem | |
| IL141157A0 (en) | Salt form of pantoprazole and pharmaceutical compositions containing the same | |
| AP2000001947A0 (en) | Novel crystalline forms of an antiviral benzidazole compound. | |
| MXPA02010458A (es) | Peptido modulador del receptor de trombopoyetina. | |
| ATE215817T1 (de) | Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis | |
| AU4011300A (en) | Compositions and methods for the treatment of immune related diseases | |
| MXPA94009086A (es) | Guanidinas sustituidas terapeuticas. | |
| WO1999014241A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| AU9731198A (en) | Histogranin peptide and their analgesic use | |
| GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| AU6849198A (en) | Neurotrypsin | |
| IL111805A0 (en) | Pharmaceutical compositions comprising dimeticone for the treatment of aphthae | |
| WO2000015797A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| GB9015774D0 (en) | Novel treatment | |
| GR1002385B (el) | Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν. | |
| AU7079300A (en) | Compositions and methods for the treatment of immune related diseases | |
| TWI226833B (en) | Pharmaceutical composition for inhibiting bone resorption |